RVTY trades 9.8% below Wall Street's consensus target of $109.83.
Last 12 months price action with 12-month analyst target path
The base valuation assumes RVTY achieves its forward estimates and maintains a stable P/E multiple of 19.1x. This scenario reflects the blended consensus of 29 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 21, 2026, Revvity, Inc. (RVTY) has a Wall Street consensus price target of $109.83, based on estimates from 29 covering analysts. With the stock currently trading at $100.00, this represents a potential upside of +9.8%. The company has a market capitalization of $11.18B.
Analyst price targets range from a low of $95.00 to a high of $124.00, representing a 26% spread in expectations. The median target of $111.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 15 analysts rating the stock as a Buy or Strong Buy,14 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, RVTY trades at a trailing P/E of 48.1x and forward P/E of 19.1x. Analysts expect EPS to grow +143.5% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $139.67, with bear and bull scenarios of $87.99 and $184.02 respectively. Model confidence stands at 46/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
WATWaters Corporation | $23.2B | $355.44 | $395.25 | +11.2% | Hold | 24.5x | 35 |
BRKRBruker Corporation | $8.7B | $57.23 | $47.67 | -16.7% | Buy | 27.0x | 32 |
MTDMettler-Toledo International Inc. | $23.1B | $1144.84 | $1392.25 | +21.6% | Hold | 24.5x | 19 |
BIOBio-Rad Laboratories, Inc. | $7.6B | $282.44 | $321.67 | +13.9% | Buy | 31.2x | 14 |
HOLXHologic, Inc. | $17.0B | $76.01 | $78.69 | +3.5% | Hold | 17.2x | 42 |
TMOThermo Fisher Scientific Inc. | $172.7B | $464.61 | $599.70 | +29.1% | Buy | 18.7x | 42 |
DHRDanaher Corporation | $125.4B | $177.17 | $230.89 | +30.3% | Buy | 21.0x | 43 |
AAgilent Technologies, Inc. | $35.9B | $127.06 | $154.75 | +21.8% | Buy | 21.0x | 41 |
QGENQiagen N.V. | $7.6B | $36.95 | $45.17 | +22.2% | Hold | 15.2x | 30 |
ILMNIllumina, Inc. | $24.6B | $161.93 | $151.40 | -6.5% | Buy | 31.0x | 50 |
Quick answers to the most common questions about buying RVTY stock.
The consensus price target for RVTY is $109.83, close to the current price of $100 (9.8% implied move). Based on 29 analyst estimates, the stock appears fairly valued near current levels.
RVTY has a consensus rating of "Buy" based on 29 Wall Street analysts. The rating breakdown is predominantly bullish, with 15 Buy/Strong Buy ratings. The consensus 12-month price target of $109.83 implies 9.8% upside from current levels.
With a forward P/E of 19.0669x, RVTY trades at a relatively low valuation. The consensus target of $109.83 implies 9.8% appreciation, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $124 for RVTY, while the most conservative target is $95. The consensus of $109.83 represents the median expectation. Our quantitative valuation model projects a bull case target of $184 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
RVTY is heavily covered by Wall Street, with 29 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 15 have Buy ratings, 14 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month RVTY stock forecast based on 29 Wall Street analysts shows a consensus price target of $109.83, with estimates ranging from $95 (bear case) to $124 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $140, with bear/bull scenarios of $88/$184.
Our quantitative valuation model calculates RVTY's fair value at $140 (base case), with a bear case of $88 and bull case of $184. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 46/100.
RVTY trades at a forward P/E ratio of 19.1x based on next-twelve-months earnings estimates compared to a trailing P/E of 48.1x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
RVTY appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $109.83 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
RVTY analyst price targets range from $95 to $124, a 26% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $109.83 consensus represents the middle ground. Our model's $88-$184 range provides an independent fundamental perspective.
Deep dive into RVTY consensus models and risk factors.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.